Join our daily newsletter At The Bell to receive exclusive market insights
- CardieX has appointed two new board members to support its global expansion strategy
- Chris Dax has been appointed Vice President and Sean Merrit has been appointed Director of Product Innovation to support
- With a new sales and marketing strategy, CardieX is targeting a minimum 20 per cent increase in sales for the FY2020 period
CardieX has appointed two new board members to support its global expansion strategy and sales growth.
SphygmoCor is the primary focus of AtCor’s business. The SphygmoCor technology device helps researchers detect and target organ damage and manage cardiovascular and renal disease in the early stages.
This is just one of the products CardieX and its subsidiary are driving sales for. The company is targeting at least a 20 per cent increase in sales for the 2020 period
Senior health executive, Chris Dax has been selected as the new Vice President of Operations to assist with the company’s plan. He has considerable pharmaceutical, biological and medical device, commercial and general management experience.
“Chris Dax is a 25-year medical device marketing and sales executive who will be primarily focused on expanding sales and marketing of AtCor’s medical device business as well as “new product” go-to-market strategy,” CEO Craig Cooper said.
CardieX has also appointed Sean Merrit as the Director of Product Innovation to assist with the launch of new products into the global health market.
Most recently, Sean worked for Cercacor’s consumer non-invasive patient technology device business. He was responsible for engineering, designing and product development for Cercacor’s device solutions.
“They have both hit the ground running and are already contributing significantly to our sales, revenue, product development, and marketing strategies for FY2020 and beyond,” Craig said.
